| Dr Timothy David Scherer, MD | |
|
100 Hitchcock Way, Manchester, NH 03104-4125 | |
| (603) 695-2500 | |
| Not Available |
| Full Name | Dr Timothy David Scherer |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 28 Years |
| Location | 100 Hitchcock Way, Manchester, New Hampshire |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1437172228 | NPI | - | NPPES |
| 30203351 | Medicaid | NH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | 10522 (New Hampshire) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mary Hitchcock Memorial Hospital | Lebanon, NH | Hospital |
| Elliot Hospital | Manchester, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dartmouth-hitchcock Clinic | 4183537509 | 1139 |
| Mary Hitchcock Memorial Hospital | 4486561164 | 964 |
News Archive
MicroStockProfit.com announces an investment report featuring Cell Therapeutics Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
A proven and cost-effective strategy for turning the tide on global AIDS still remains significantly underutilized, World Vision warned in advance of World AIDS Day. Efforts to prevent mother-to-baby transmission of HIV must be urgently scaled up in high-prevalence countries to avoid needless infection of children, the Christian humanitarian organization said.
Abbott announced today that it has received CE Mark approval for the world's first drug eluting bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease. Abbott's BVS device restores blood flow by opening a clogged vessel and providing support to the vessel until the device dissolves within approximately two years, leaving patients with a treated vessel free of a permanent metallic implant. Abbott's BVS device will be commercialized under the brand name ABSORB.
In one of the greatest advances in medicine in decades, Hepatitis C is now largely curable. Over 200,000 Australians suffer from Hepatitis C. However the US manufacturer, Gilead Sciences Inc is attempting to charge the PBS $84,000 for a 12 week course of medication that costs under $200 dollars to manufacture.
A new class of nanoparticles, synthesized by a UC Davis research team to prevent premature drug release, holds promise for greater accuracy and effectiveness in delivering cancer drugs to tumors. The work is published online in Angewandte Chemie, a leading international chemistry journal.
› Verified 6 days ago
| Entity Name | Mary Hitchcock Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023092053 PECOS PAC ID: 4486561164 Enrollment ID: O20031126000258 |
News Archive
MicroStockProfit.com announces an investment report featuring Cell Therapeutics Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
A proven and cost-effective strategy for turning the tide on global AIDS still remains significantly underutilized, World Vision warned in advance of World AIDS Day. Efforts to prevent mother-to-baby transmission of HIV must be urgently scaled up in high-prevalence countries to avoid needless infection of children, the Christian humanitarian organization said.
Abbott announced today that it has received CE Mark approval for the world's first drug eluting bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease. Abbott's BVS device restores blood flow by opening a clogged vessel and providing support to the vessel until the device dissolves within approximately two years, leaving patients with a treated vessel free of a permanent metallic implant. Abbott's BVS device will be commercialized under the brand name ABSORB.
In one of the greatest advances in medicine in decades, Hepatitis C is now largely curable. Over 200,000 Australians suffer from Hepatitis C. However the US manufacturer, Gilead Sciences Inc is attempting to charge the PBS $84,000 for a 12 week course of medication that costs under $200 dollars to manufacture.
A new class of nanoparticles, synthesized by a UC Davis research team to prevent premature drug release, holds promise for greater accuracy and effectiveness in delivering cancer drugs to tumors. The work is published online in Angewandte Chemie, a leading international chemistry journal.
› Verified 6 days ago
| Entity Name | Dartmouth-hitchcock Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548210198 PECOS PAC ID: 4183537509 Enrollment ID: O20040809000442 |
News Archive
MicroStockProfit.com announces an investment report featuring Cell Therapeutics Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
A proven and cost-effective strategy for turning the tide on global AIDS still remains significantly underutilized, World Vision warned in advance of World AIDS Day. Efforts to prevent mother-to-baby transmission of HIV must be urgently scaled up in high-prevalence countries to avoid needless infection of children, the Christian humanitarian organization said.
Abbott announced today that it has received CE Mark approval for the world's first drug eluting bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease. Abbott's BVS device restores blood flow by opening a clogged vessel and providing support to the vessel until the device dissolves within approximately two years, leaving patients with a treated vessel free of a permanent metallic implant. Abbott's BVS device will be commercialized under the brand name ABSORB.
In one of the greatest advances in medicine in decades, Hepatitis C is now largely curable. Over 200,000 Australians suffer from Hepatitis C. However the US manufacturer, Gilead Sciences Inc is attempting to charge the PBS $84,000 for a 12 week course of medication that costs under $200 dollars to manufacture.
A new class of nanoparticles, synthesized by a UC Davis research team to prevent premature drug release, holds promise for greater accuracy and effectiveness in delivering cancer drugs to tumors. The work is published online in Angewandte Chemie, a leading international chemistry journal.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Timothy David Scherer, MD Po Box 810, Hanover, NH 03755-0810 Ph: (603) 308-1467 | Dr Timothy David Scherer, MD 100 Hitchcock Way, Manchester, NH 03104-4125 Ph: (603) 695-2500 |
News Archive
MicroStockProfit.com announces an investment report featuring Cell Therapeutics Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
A proven and cost-effective strategy for turning the tide on global AIDS still remains significantly underutilized, World Vision warned in advance of World AIDS Day. Efforts to prevent mother-to-baby transmission of HIV must be urgently scaled up in high-prevalence countries to avoid needless infection of children, the Christian humanitarian organization said.
Abbott announced today that it has received CE Mark approval for the world's first drug eluting bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease. Abbott's BVS device restores blood flow by opening a clogged vessel and providing support to the vessel until the device dissolves within approximately two years, leaving patients with a treated vessel free of a permanent metallic implant. Abbott's BVS device will be commercialized under the brand name ABSORB.
In one of the greatest advances in medicine in decades, Hepatitis C is now largely curable. Over 200,000 Australians suffer from Hepatitis C. However the US manufacturer, Gilead Sciences Inc is attempting to charge the PBS $84,000 for a 12 week course of medication that costs under $200 dollars to manufacture.
A new class of nanoparticles, synthesized by a UC Davis research team to prevent premature drug release, holds promise for greater accuracy and effectiveness in delivering cancer drugs to tumors. The work is published online in Angewandte Chemie, a leading international chemistry journal.
› Verified 6 days ago
Jenny Lin, MD Gastroenterology Medicare: Medicare Enrolled Practice Location: 100 Hitchcock Way, Manchester, NH 03104 Phone: 603-695-2500 | |
Dr. Douglas F. Marks Jr., M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 87 Mcgregor St, Ste 4100, Manchester, NH 03102 Phone: 603-695-2500 Fax: 603-695-2647 | |
Dr. Jose E. Lozano, M.D. Gastroenterology Medicare: Medicare Enrolled Practice Location: 718 Smyth Rd, Manchester Va, Manchester, NH 03104 Phone: 603-624-4366 | |
Frances Jensen, M.D. Gastroenterology Medicare: Medicare Enrolled Practice Location: 456 Union St, Manchester, NH 03103 Phone: 866-679-0381 | |
Dr. Victor Gordan, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 718 Smyth Rd, Manchester, NH 03104 Phone: 603-624-4366 Fax: 603-626-6559 | |
Dr. Peter Wilson Shaw, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 100 Mcgregor St # Stb, Manchester, NH 03102 Phone: 603-663-6350 | |
Dr. Goran Broketa, MD Gastroenterology Medicare: Medicare Enrolled Practice Location: 718 Smyth Rd, Manchester, NH 03104 Phone: 603-624-4366 Fax: 603-629-3217 |